KEGG   DRUG: D09927Help
Entry
D09927                      Drug                                   

Name
Lorvotuzumab mertansine (USAN/INN)
Formula
C6504H10074N1758O2004S46
Exact mass
146342.7576
Mol weight
146433.1466
Sequence
(Heavy chain) QVQLVESGGG VVQPGRSLRL SCAASGFTFS SFGMHWVRQA
PGKGLEWVAY ISSGSFTIYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCARMR
KGYAMDYWGQ GTLVTVSSAS TKGPSVFPLA PSSKSTSGGT AALGCLVKDY FPEPVTVSWN
SGALTSGVHT FPAVLQSSGL YSLSSVVTVP SSSLGTQTYI CNVNHKPSNT KVDKKVEPKS
CDKTHTCPPC PAPELLGGPS VFLFPPKPKD TLMISRTPEV TCVVVDVSHE DPEVKFNWYV
DGVEVHNAKT KPREEQYNST YRVVSVLTVL HQDWLNGKEY KCKVSNKALP APIEKTISKA
KGQPREPQVY TLPPSRDELT KNQVSLTCLV KGFYPSDIAV EWESNGQPEN NYKTTPPVLD
SDGSFFLYSK LTVDKSRWQQ GNVFSCSVMH EALHNHYTQK SLSLSPGK
(Disulfide bridge: 22-96; 145-201; 262-322; 368-426, Dimer: 227; 230)
(Light chain) DVVMTQSPLS LPVTLGQPAS ISCRSSQIII HSDGNTYLEW
FQQRPGQSPR RLIYKVSNRF SGVPDRFSGS GSGTDFTLKI SRVEAEDVGV YYCFQGSHVP
HTFGQGTKVE IKRTVAAPSV FIFPPSDEQL KSGTASVVCL LNNFYPREAK VQWKVDNALQ
SGNSQESVTE QDSKDSTYSL SSTLTLSKAD YEKHKVYACE VTHQGLSSPV TKSFNRGEC
(Disulfide bridge: 23-93; 139-199; H221-L219, Dimer)
  Type
Peptide
Activity
Oncology
Comment
Lorvotuzumab mertansine is a conjugate of the maytansinoid drug DM1 [CPD:C20259] to the CD56-antibody.
Target
CD56 (NCAM) [HSA:4684] [KO:K06491]
  Pathway
hsa04514  Cell adhesion molecules (CAMs)  
 
Brite
Target-based classification of drugs [BR:br08310]
 Others
  Heparin binding proteins
   NCAM (CD56)
    Lorvotuzumab mertansine
     D09927  Lorvotuzumab mertansine (USAN/INN)
BRITE hierarchy
Other DBs
CAS: 
1008106-64-6
PubChem: 
LinkDB All DBs

» Japanese version   » Back

DBGET integrated database retrieval system